Clinical Trials: Clinical Trial Logistics

Global Clinical Trial Logistics: Managing Multi-Country Supply Chains

Posted on digi By digi

Clinical trials have become increasingly globalized, with studies spanning dozens of countries and hundreds of sites. This globalization introduces unique challenges for supply chain management, requiring sponsors to navigate customs, local regulations, and multi-vendor networks. For US sponsors, the FDA expects that investigational product (IMP) integrity, accountability, and documentation remain intact throughout international supply chains.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Direct-to-Patient Logistics in Clinical Trials: Compliance and Oversight

Posted on digi By digi

Direct-to-Patient (DTP) logistics represents a paradigm shift in clinical trial supply chains. Instead of relying solely on investigational sites, IMPs (Investigational Medicinal Products) are delivered directly to participants’ homes. This model supports decentralized clinical trials (DCTs), increases patient recruitment and retention, and minimizes site visit burdens. For US sponsors, the FDA recognizes DTP as permissible under certain conditions, provided that supply chain integrity, accountability, and documentation are maintained.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Temperature Excursion Management in Clinical Trial Logistics

Posted on digi By digi

Temperature excursions—instances where investigational products are exposed to conditions outside approved ranges—are among the most common risks in clinical trial logistics. For US sponsors, the FDA requires full accountability and documentation of any excursion affecting investigational medicinal products (IMPs). Improper management compromises product stability, patient safety, and data integrity. In decentralized or global trials, excursions can occur at multiple points: courier transport, depot storage, or site-level handling.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Risk Management in Clinical Trial Logistics and Supply Chains

Posted on digi By digi

Clinical trial logistics are inherently high-risk due to the complexity of global supply chains, reliance on third-party vendors, and temperature-sensitive investigational products (IMPs). For US sponsors, the FDA requires proactive identification and mitigation of risks throughout the supply chain. Failures can jeopardize patient safety, trial timelines, and regulatory approvals.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Digital Solutions for Clinical Trial Logistics and Oversight

Posted on digi By digi

Clinical trial logistics have traditionally relied on manual processes, paper-based documentation, and fragmented vendor oversight. In today’s regulatory environment, these approaches are insufficient for ensuring inspection readiness. For US sponsors, the FDA emphasizes electronic data integrity, real-time oversight, and validated systems for supply chain management. Digital solutions—including Interactive Response Technology (IRT), Clinical Trial Management Systems (CTMS), and electronic Trial Master Files (eTMF)—are now indispensable tools for compliance.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Contingency Planning for Clinical Trial Supply Continuity

Posted on digi By digi

Clinical trial supply chains are vulnerable to disruptions ranging from customs delays to natural disasters. For US sponsors, ensuring supply continuity is not only an operational requirement but also a compliance obligation. FDA inspections consistently highlight deficiencies in contingency planning as a source of trial delays and data integrity risks.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Site Supply Management in Clinical Trial Logistics

Posted on digi By digi

Investigator sites are the final point of control before investigational medicinal products (IMPs) reach patients. Effective site supply management ensures that IMPs are stored, dispensed, reconciled, and returned in compliance with FDA requirements. For US sponsors, inadequate site-level oversight is one of the most frequent triggers of Form 483 observations during FDA inspections. Failures in accountability or storage can directly compromise patient safety and trial data integrity.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Training and Competency in Clinical Trial Logistics

Posted on digi By digi

Clinical trial logistics involve complex processes—storage, distribution, accountability, and destruction of investigational medicinal products (IMPs). For US sponsors, the FDA requires that all staff handling trial supplies are adequately trained and qualified. Inadequate training often leads to errors in IMP accountability, temperature excursion management, and documentation, which can result in regulatory findings. Competency in logistics is not optional; it is a compliance requirement.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Courier Oversight in Clinical Trial Logistics

Posted on digi By digi

Couriers form the critical link between depots and clinical trial sites—or in direct-to-patient (DTP) models, between depots and patients’ homes. For US sponsors, courier oversight is a high-risk area under FDA inspections, with deficiencies leading to Form 483s and delayed trial timelines. Couriers manage temperature-sensitive products, chain-of-custody documentation, and timely delivery, making them compliance-critical partners rather than just logistics providers.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Depot Management and Oversight in Clinical Trial Logistics

Posted on digi By digi

Depots are central nodes in the clinical trial supply chain, responsible for storing, distributing, and reconciling investigational medicinal products (IMPs). For US sponsors, the FDA requires that depots operate under Good Distribution Practice (GDP) and maintain full accountability for IMP disposition. Failures in depot oversight can result in temperature excursions, data integrity issues, and regulatory citations. As clinical trials expand globally, depot networks often involve multiple vendors, increasing oversight complexity.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance